Search
for
Sort by
Research 31–60 of 336
- Targeted therapy in melanoma
- Progress in Dermatology and Venereology in 2023 as reflected in the Journal of the European Academy of Dermatology and Venereology
- America - A Diversity of Life Styles.
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Biological therapy in the treatment of melanoma
- Endocrine treatment of benign prostatichypertrophy: Current concepts
- Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF V 600R mutation
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- RASopathic alopecia: Hair changes associated with vemurafenib therapy
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance
- Psoriatic Skin Lesions Induced by Certolizumab Pegol
- Dermatologic Reactions to Targeted Therapy
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Dermoscopy — 4th Conference of the Section of Dermoscopy and Other Skin Imaging Techniques (DiTOS) of the Polish Dermatological Society — Abstracts
- The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Sorafenib-induced Facial Acneiform Eruption
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- The PDGF/PDGFR pathway as a drug target
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Regulation of melanocyte stem cell behavior by the niche microenvironment
- Male androgenetic alopecia (Part II)